A Narrative Review of the Efficacy of Acupuncture in Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients.
📄 Abstract
ObjectiveThis review synthesizes current evidence on the efficacy of acupuncture in managing chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients, focusing on its mechanisms, clinical applications, and future research directions.MethodsThis narrative review synthesizes and critically appraises findings from randomized controlled trials (RCTs), meta-analyses, and preclinical studies, evaluating acupuncture's impact on pain relief, neurological function, and quality of life. Key databases were searched for studies published up to 2024.ResultsNineteen RCTs (
Confidence:
0.06
· 3 полей извлечено
Идентификация (6 полей)
Target
—
0.00
Alt. target
—
0.00
Protein family
—
0.00
Functional class
—
0.00
Subcellular loc.
—
0.00
Isoforms (metab/obesity)
—
0.00
Механизм действия (21 полей)
Mechanism
—
0.00
Mutations (obesity/lean)
—
0.00
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
—
0.00
Appetite
—
0.00
Fat metabolism
—
0.00
Lipolysis
—
0.00
Thermogenesis
—
0.00
Muscle metabolism
—
0.00
Inflammation
—
0.00
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
—
0.00
Cell death
—
0.00
Adipocyte fibrosis
—
0.00
Upstream (biochem)
—
0.00
Upstream (physiol)
—
0.00
Downstream (biochem)
—
0.00
Downstream (physiol)
—
0.00
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
Selenium attenuates paclitaxel-induced peripheral neuropathy in rat sciatic nerve
0.90
In silico
—
0.00
Genetic association
BDNF Val66Met protects oxaliplatin-induced peripheral neuropathy; prediction models of persistent taxane-induced peripheral neuropathy using whole-exome sequencing; clinical and genome-wide analysis of multiple severe cisplatin-induced neurotoxicities
0.90
Ex vivo
—
0.00
Animal model
rat
0.90
Diet/model
—
0.00
Клиника (11 полей)
Drug
—
0.00
Indication
—
0.00
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
—
0.00
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
—
0.00